Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 9:00 a.m. Eastern Time. The conference will be held at The Waldorf Astoria, New York, NY.
Category: Rheumatology
Positive Results Reported for Potential Humira Biosimilar
The comparative, confirmatory REFLECTIONS B538-02 study has met its primary objective by demonstrating equivalent efficacy, as measured by the American College of Rheumatology 20 response rate at week 12, between PF-06410293 and Humira . PF-06410293, a monoclonal antibody, is being developed as a potential biosimilar to Humira.